Abstract |
Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists ( DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non-ergot DAs. We evaluated the effects of four DAs ( pergolide, cabergoline, ropinirole, pramipexole) on morphology and function of heart valves in patients with Parkinson's disease (PD) to determine the frequency and clinical relevance of DA-induced VHD. A total of 85 patients treated with ergot or non-ergot DAs and 38 age-matched controls were evaluated by transthoracic echocardiography. Valvular pathology was assessed by established criteria of valvular regurgitation and a VHD scoring system. Both grading systems revealed increased frequency of VHD in ergot DA patients compared to both non-ergot DA patients and controls with 22% of ergot DA patients having moderate VHD versus 3% of non-ergot DA patients and none of controls (P = 0.001). We did not find correlations of echocardiographic findings with duration/cumulative dose of treatment, age, or vascular risk factors. Our data suggest that ergot DAs are associated with higher prevalence of VHD compared to non-ergot DAs and controls. Standard echocardiography seems sufficient to detect VHD in PD patients treated with DAs.
|
Authors | Susann Junghanns, Joerg T Fuhrmann, Gregor Simonis, Christian Oelwein, Rainer Koch, Ruth H Strasser, Heinz Reichmann, Alexander Storch |
Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 22
Issue 2
Pg. 234-8
(Jan 15 2007)
ISSN: 0885-3185 [Print] United States |
PMID | 17094087
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | (c) 2006 Movement Disorder Society. |
Chemical References |
- Benzothiazoles
- Dopamine Agonists
- Ergolines
- Indoles
- ropinirole
- Pergolide
- Pramipexole
- Cabergoline
|
Topics |
- Benzothiazoles
(therapeutic use)
- Cabergoline
- Dopamine Agonists
(therapeutic use)
- Double-Blind Method
- Echocardiography
(instrumentation)
- Ergolines
(therapeutic use)
- Female
- Fibrosis
(epidemiology, pathology)
- Heart Valve Diseases
(diagnosis, epidemiology, pathology)
- Humans
- Hypertrophy, Left Ventricular
(diagnosis, epidemiology)
- Indoles
(therapeutic use)
- Male
- Middle Aged
- Mitral Valve Insufficiency
(diagnosis, epidemiology)
- Parkinson Disease
(drug therapy, epidemiology)
- Pergolide
(therapeutic use)
- Pramipexole
- Severity of Illness Index
- Tricuspid Valve Insufficiency
(diagnosis, epidemiology)
|